CellMosaic, Inc.

NovaBioAssays Inc, based in Woburn, MA, specializes in providing analytical and bioanalytical solutions to the global biotech and pharmaceutical industries. The company is committed to delivering high-quality data, helping clients make critical decisions in therapeutic discovery and development while offering competitive services using advanced technology. With a focus on therapeutic proteins, oligonucleotides, small molecules, and gene therapy, NovaBioAssays employs cutting-edge methods for bioanalysis, characterization, and strategy design. Their dedicated team partners closely with clients to accelerate medicine innovation and enhance patient outcomes through reliable expertise and services. Generated from the website

CBSET Inc is a leading preclinical science company based in Lexington, MA, offering innovative solutions for medical device testing, drug cell-based therapies, histopathology morphometry, and education training. With a unique integrated approach, CBSET combines in vivo testing, detailed histopathological analysis, and computational modeling to address complex scientific questions and improve regulatory efficiency. CBSET's specialized expertise lies in the pre-clinical evaluation and development of novel diagnostic and therapeutic medical devices, as well as the evaluation of pharmacology, toxicity, and biodistribution of drugs and cell-based therapeutics. Their commitment to education extends from sharing groundbreaking data with the scientific community to training physicians on new procedures and techniques, making CBSET a trusted partner in advancing medical innovation and improving lives.Generated from the website

HiFiBiO Therapeutics is a clinical-stage global biotech company based in Cambridge, MA. They are dedicated to revolutionizing the development of immunotherapies by utilizing their unique high-resolution translational platform, DIS, which provides an unprecedented understanding of immune dysregulation at the single cell level. Their goal is to enhance the probability of success for immunotherapies and improve patient outcomes through single-cell precision. With a focus on single cell science, HiFiBiO Therapeutics applies this approach at every stage of drug development, from target discovery to predictive biomarkers. This enables them to rapidly advance new therapeutics into the clinic, ultimately aiming to unlock the curative powers of the immune system. Through strategic collaborations and groundbreaking initiatives, they are at the forefront of personalized immunotherapies and have been recognized for their innovative Drug Intelligence Science (DIS) platform.Generated from the website